Who Buys Imatinib from India — 456 Importers Behind a $29.3M Market
India's imatinib import market is served by 456 active buyers who collectively imported $29.3M across 1,726 shipments. H.ESSERS & ZONEN INTERNATIONAL TRAN (BELGIUM) leads with a 11.4% market share, followed by COOPER PHARMA and AUROLOGISTICS LLC, (AUROBINDO PHARM. The top 5 buyers together control 33.8% of total import value, reflecting a moderately competitive buyer landscape.
Top Imatinib Importers — Ranked by Import Value
H.ESSERS & ZONEN INTERNATIONAL TRAN (BELGIUM) is the leading imatinib importer from India, holding a 11.4% share of the $29.3M market across 1,726 shipments from 456 buyers. The top 5 buyers — H.ESSERS & ZONEN INTERNATIONAL TRAN (BELGIUM), COOPER PHARMA (MOROCCO), AUROLOGISTICS LLC, (AUROBINDO PHARM (UNITED STATES), AUROBINDO PHARMA USA INC (UNITED STATES), OOO"JODAS EXPOIM" (RUSSIA) — collectively control 33.8% of total import value.
Top Imatinib Buyers & Importers
Ranked by import value · 456 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | H.ESSERS & ZONEN INTERNATIONAL TRANBELGIUM IMATINIB ORION 100MG CAPSULES PACK SIZE 12 X 10SIMATINIB MESYLATE TABLETS 400MG ( IMATINIMATINIB CIPLA 400 MG CAPSULES | $3.3M | 5 | 11.4% |
| 2 | COOPER PHARMAMOROCCO IMATINIB COOPER 100 MG CAPSULES ( IMATINIMATINIB COOPER 100 MG CAPSULES 100MG) [1133X10X10'S]IMATINIB COOPER 100 MG CAPSULES IMATIN | $1.9M | 5 | 6.4% |
| 3 | AUROLOGISTICS LLC, (AUROBINDO PHARMUNITED STATES IMATINIB MESYLATE TABLETS 400 MG IMATINIMATINIB MESYLATE TABLETS 400 MGIMATINIB MESYLATE TABLETS 400 MG - US | $1.8M | 5 | 6.1% |
| 4 | AUROBINDO PHARMA USA INCUNITED STATES IMATINIB MESYLATE TABLETS 400 MG IMATINIMATINIB MESYLATE TABLETS 400 MGIMATINIB MESYLATE TABLETS 400 MG - US | $1.5M | 5 | 5.2% |
| 5 | OOO"JODAS EXPOIM"RUSSIA IMATINIB TABLETS 400MGIMATINIB TABLETS 100MG | $1.4M | 5 | 4.6% |
| 6 | HABIB BANK LIMITEDPAKISTAN IMATIB ALPHA 100 CAPSULESIMATIB ALPHA 100 CAPSULES NOS | $1.3M | 5 | 4.4% |
| 7 | JS BANK LTD.PAKISTAN IMATIB ALPHA 100 CAPSULESIMATIB ALPHA 100 CAPSULES NOS | $1.2M | 5 | 4.2% |
| 8 | AUROBINDO PHARMA USA., INC,UNITED STATES IMATINIB MESYLATE TABLETS 400 MG IMATINIMATINIB MESYLATE TABLETS 400 MGIMATINIB MESYLATE TABLETS 400 MG - US | $1.2M | 5 | 4.1% |
| 9 | MEDPRO PHARMACEUTICA (PTY) LTDSOUTH AFRICA IMAVEC 400MG CAPSULLES [3825X3X10'S]NOSIMAVEC 100MG CAPSULE IMATINIB MESYLATEIMAVEC 100MG CAPSULE CAPSULES 100MG) | $857.1K | 5 | 2.9% |
| 10 | OOO JODAS EXPOIMRUSSIA IMATINIB TABLETS 400MGIMATINIB TABLETS 100MG | $690.4K | 5 | 2.4% |
| 11 | SUN PHARMA ANZ PTY LTD.,AUSTRALIA IMATINIB MESYLATE TABLETS 400MG (IMATINIIMATINIB GH 400 MG CAPSULESIMATINIB MESYLATE TABLETS 100MG (IMATINI | $603.2K | 5 | 2.1% |
| 12 | OOOJODAS EXPOIMRUSSIA IMATINIB TABLETS 400MGIMATINIB TABLETS 100MG | $576.4K | 5 | 2.0% |
| 13 | QUALLENT PHARMACEUTICALS HEALTH LLCUNITED STATES IMATINIB MESYLATE TABLETS 400 MG IMATINIMATINIB MESYLATE TABLETS 400 MGIMATINIB MESYLATE TABLETS 400 MG - US | $553.2K | 5 | 1.9% |
| 14 | AUROBINDO PHARMA USA., INCUNITED STATES IMATINIB MESYLATE TABLETS 400 MG IMATINIMATINIB MESYLATE TABLETS 400 MGIMATINIB MESYLATE TABLETS 400 MG - US | $476.1K | 5 | 1.6% |
| 15 | SUN PHARMACEUTICAL INDUSTRIES,INC.UNITED STATES IMATINIB MESYLATE TABLETS 400MG (IMATINIIMATINIB GH 400 MG CAPSULESIMATINIB MESYLATE TABLETS 100MG (IMATINI | $454.4K | 5 | 1.6% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Imatinib — and from which countries?
Flow of Imatinib exports from India: each country's share and the named importers behind the numbers
Imatinib — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $7.1M through 100 shipments. This represents a market share of 24.3% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• AUROLOGISTICS LLC, (AUROBINDO PHARM - $1.8M (25.2% of country's total business)
• AUROBINDO PHARMA USA INC - $1.5M (21.6% of country's total business)
• AUROBINDO PHARMA USA., INC, - $1.2M (16.8% of country's total business)
• QUALLENT PHARMACEUTICALS HEALTH LLC - $553.2K (7.8% of country's total business)
• AUROBINDO PHARMA USA., INC - $476.1K (6.7% of country's total business)
• Rest of United States's importers - $1.6M (21.9% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $71.1K, indicating premium pricing strategy compared to the market average of $17.0K.
United States is a key market for Imatinib imports, representing 24.3% of total trade value.
2Belgium
Belgium emerges as the second largest importing country, achieving a total trade value of $3.6M through 6 shipments. This represents a market share of 12.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Belgium has a diverse importer base, with their top importers including:
• H.ESSERS & ZONEN INTERNATIONAL TRAN - $3.3M (91.6% of country's total business)
Key Insight: Belgium demonstrates strong market positioning with an average shipment value of $607.3K, indicating premium pricing strategy compared to the market average of $17.0K.
Belgium is a key market for Imatinib imports, representing 12.4% of total trade value.
3Pakistan
Pakistan emerges as the third largest importing country, achieving a total trade value of $3.2M through 32 shipments. This represents a market share of 11.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Pakistan has a diverse importer base, with their top importers including:
• HABIB BANK LIMITED - $1.3M (39.7% of country's total business)
• JS BANK LTD. - $1.2M (38.0% of country's total business)
Key Insight: Pakistan demonstrates strong market positioning with an average shipment value of $101.4K, indicating premium pricing strategy compared to the market average of $17.0K.
Pakistan is a key market for Imatinib imports, representing 11.1% of total trade value.
4Russia
Russia emerges as the fourth largest importing country, achieving a total trade value of $2.7M through 24 shipments. This represents a market share of 9.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Russia has a diverse importer base, with their top importers including:
• OOO"JODAS EXPOIM" - $1.4M (50.6% of country's total business)
• OOO JODAS EXPOIM - $690.4K (25.9% of country's total business)
• OOOJODAS EXPOIM - $576.4K (21.6% of country's total business)
Key Insight: Russia demonstrates strong market positioning with an average shipment value of $111.2K, indicating premium pricing strategy compared to the market average of $17.0K.
Russia is a key market for Imatinib imports, representing 9.1% of total trade value.
5Morocco
Morocco emerges as the fifth largest importing country, achieving a total trade value of $2.4M through 16 shipments. This represents a market share of 8.2% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Morocco has a diverse importer base, with their top importers including:
• COOPER PHARMA - $1.9M (78.0% of country's total business)
Key Insight: Morocco demonstrates strong market positioning with an average shipment value of $150.7K, indicating premium pricing strategy compared to the market average of $17.0K.
Morocco is a key market for Imatinib imports, representing 8.2% of total trade value.
Buyer Segment Analysis
TransData Nexus Imatinib buyer market intelligence
1Buyer Segment Analysis
The importation of Imatinib from India involves a diverse array of buyers, each falling into specific categories:
- Distributors: Entities like H. Essers & Zonen International Transport (Belgium) and Cooper Pharma (Morocco) function as intermediaries, purchasing large quantities of Imatinib to supply regional markets. Their buying behavior is characterized by bulk orders and a focus on maintaining a steady supply chain to meet market demand.
- Contract Manufacturers: Companies such as Aurobindo Pharma USA Inc. and Aurobindo Pharma USA., Inc. (United States) import Imatinib for further processing or formulation. Their procurement patterns are aligned with production schedules, often involving substantial volumes to ensure continuous manufacturing operations.
- Re-exporters: Firms like OOO "Jodas Expoim" (Russia) and OOO Jodas Expoim (Russia) may import Imatinib with the intent to re-export to neighboring markets. Their purchasing behavior is influenced by regional demand fluctuations and trade agreements, leading to variable order sizes and frequencies.
- Financial Institutions: Entities such as Habib Bank Limited and JS Bank Ltd. (Pakistan) are listed among the top buyers. While not traditional pharmaceutical buyers, their involvement suggests roles in facilitating large-scale procurement, possibly for government or large healthcare institutions. Their buying patterns would be characterized by significant, periodic transactions aligned with institutional needs.
Each segment's procurement strategies are tailored to their operational roles, with distributors focusing on market supply, contract manufacturers on production continuity, re-exporters on regional trade dynamics, and financial institutions on facilitating large-scale acquisitions.
Country-Specific Import Regulations
TransData Nexus Imatinib buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process for Imatinib: Importers must ensure that Imatinib is FDA-approved. The process involves submitting a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) for generics.
3. Estimated Timeline for Registration: The FDA review process typically takes 10 months for standard applications, though priority reviews can be expedited to 6 months.
4. Import Tariff/Duty for HS 30049049: Pharmaceutical products under HS code 30049049 are generally duty-free in the U.S.
Belgium
1. Drug Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
2. Import Registration Process for Imatinib: Importers must obtain a marketing authorization from FAMHP, which includes submitting a dossier demonstrating the product's quality, safety, and efficacy.
3. Estimated Timeline for Registration: The evaluation process can take up to 210 days, excluding any clock stops for additional information requests.
4. Import Tariff/Duty for HS 30049049: As part of the European Union, Belgium applies a 0% tariff on pharmaceutical products under this HS code.
Pakistan
1. Drug Regulatory Authority: Drug Regulatory Authority of Pakistan (DRAP).
2. Import Registration Process for Imatinib: Importers must register the product with DRAP by submitting an application that includes product details, manufacturing information, and evidence of compliance with quality standards.
3. Estimated Timeline for Registration: The registration process can take approximately 12 to 18 months, depending on the completeness of the application and any additional information required.
4. Import Tariff/Duty for HS 30049049: Pakistan imposes a customs duty of 5% on pharmaceutical products under this HS code.
Russia
1. Drug Regulatory Authority: Ministry of Health of the Russian Federation.
2. Import Registration Process for Imatinib: Importers must obtain a registration certificate from the Ministry of Health, which involves submitting a comprehensive dossier and undergoing a state examination of the product.
3. Estimated Timeline for Registration: The process typically takes 12 to 14 months, subject to the submission of all required documentation and successful completion of evaluations.
4. Import Tariff/Duty for HS 30049049: Russia applies a 0% import duty on pharmaceutical products under this HS code.
Morocco
1. Drug Regulatory Authority: Ministry of Health, Directorate of Medicines and Pharmacy.
2. Import Registration Process for Imatinib: Importers must obtain a marketing authorization by submitting an application that includes product specifications, clinical data, and manufacturing details.
3. Estimated Timeline for Registration: The registration process can take between 12 to 24 months, depending on the complexity of the application and any additional information requested.
4. Import Tariff/Duty for HS 30049049: Morocco imposes a customs duty of 2.5% on pharmaceutical products under this HS code.
Demand Drivers & Market Opportunity
TransData Nexus Imatinib buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Imatinib across various countries is primarily driven by the prevalence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), conditions for which Imatinib is a first-line treatment. According to the World Health Organization (WHO), CML accounts for approximately 15% of all leukemia cases worldwide, indicating a significant patient population requiring Imatinib therapy.
Government healthcare programs and the expansion of universal health coverage have further bolstered demand. Many countries have included Imatinib in their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which recommends Imatinib for the treatment of CML and GIST. This inclusion facilitates procurement through government tenders and international organizations like UNICEF and the Global Fund, ensuring broader access to the medication. The presence of 456 buyers across 119 countries, as per TransData Nexus data, underscores the global reach and critical need for Imatinib in managing these life-threatening conditions.
Common Questions — Imatinib Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest imatinib buyer importing from India?
Based on import volume and value, H.ESSERS & ZONEN INTERNATIONAL TRAN (BELGIUM) leads with $3.3M in imports and a 11.4% market share — the highest of any single imatinib importer. COOPER PHARMA (MOROCCO) and AUROLOGISTICS LLC, (AUROBINDO PHARM (UNITED STATES) are the next largest buyers.
QHow many companies buy imatinib from India?
There are 456 active imatinib buyers importing from India, with a combined market of $29.3M across 1,726 shipments to 119 countries. The top 5 buyers hold 33.8% of total import value, while the remaining 451 buyers handle the other 66.2%.
QWhich countries import the most imatinib from India?
The top importing countries for imatinib from India are United States (24.3%), Belgium (12.4%), Pakistan (11.1%), Russia (9.1%), Morocco (8.2%). These markets represent the largest demand centres for Indian pharmaceutical exports of imatinib, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for imatinib from India?
The average import transaction value for imatinib from India is $17.0K, with an average unit price of $16.53 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Imatinib buyer market intelligence
1Buyer Segment Analysis
The importation of Imatinib from India involves a diverse array of buyers, each falling into specific categories:
- Distributors: Entities like H. Essers & Zonen International Transport (Belgium) and Cooper Pharma (Morocco) function as intermediaries, purchasing large quantities of Imatinib to supply regional markets. Their buying behavior is characterized by bulk orders and a focus on maintaining a steady supply chain to meet market demand.
- Contract Manufacturers: Companies such as Aurobindo Pharma USA Inc. and Aurobindo Pharma USA., Inc. (United States) import Imatinib for further processing or formulation. Their procurement patterns are aligned with production schedules, often involving substantial volumes to ensure continuous manufacturing operations.
- Re-exporters: Firms like OOO "Jodas Expoim" (Russia) and OOO Jodas Expoim (Russia) may import Imatinib with the intent to re-export to neighboring markets. Their purchasing behavior is influenced by regional demand fluctuations and trade agreements, leading to variable order sizes and frequencies.
- Financial Institutions: Entities such as Habib Bank Limited and JS Bank Ltd. (Pakistan) are listed among the top buyers. While not traditional pharmaceutical buyers, their involvement suggests roles in facilitating large-scale procurement, possibly for government or large healthcare institutions. Their buying patterns would be characterized by significant, periodic transactions aligned with institutional needs.
Each segment's procurement strategies are tailored to their operational roles, with distributors focusing on market supply, contract manufacturers on production continuity, re-exporters on regional trade dynamics, and financial institutions on facilitating large-scale acquisitions.
Country-Specific Import Regulations
TransData Nexus Imatinib buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process for Imatinib: Importers must ensure that Imatinib is FDA-approved. The process involves submitting a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) for generics.
3. Estimated Timeline for Registration: The FDA review process typically takes 10 months for standard applications, though priority reviews can be expedited to 6 months.
4. Import Tariff/Duty for HS 30049049: Pharmaceutical products under HS code 30049049 are generally duty-free in the U.S.
Belgium
1. Drug Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
2. Import Registration Process for Imatinib: Importers must obtain a marketing authorization from FAMHP, which includes submitting a dossier demonstrating the product's quality, safety, and efficacy.
3. Estimated Timeline for Registration: The evaluation process can take up to 210 days, excluding any clock stops for additional information requests.
4. Import Tariff/Duty for HS 30049049: As part of the European Union, Belgium applies a 0% tariff on pharmaceutical products under this HS code.
Pakistan
1. Drug Regulatory Authority: Drug Regulatory Authority of Pakistan (DRAP).
2. Import Registration Process for Imatinib: Importers must register the product with DRAP by submitting an application that includes product details, manufacturing information, and evidence of compliance with quality standards.
3. Estimated Timeline for Registration: The registration process can take approximately 12 to 18 months, depending on the completeness of the application and any additional information required.
4. Import Tariff/Duty for HS 30049049: Pakistan imposes a customs duty of 5% on pharmaceutical products under this HS code.
Russia
1. Drug Regulatory Authority: Ministry of Health of the Russian Federation.
2. Import Registration Process for Imatinib: Importers must obtain a registration certificate from the Ministry of Health, which involves submitting a comprehensive dossier and undergoing a state examination of the product.
3. Estimated Timeline for Registration: The process typically takes 12 to 14 months, subject to the submission of all required documentation and successful completion of evaluations.
4. Import Tariff/Duty for HS 30049049: Russia applies a 0% import duty on pharmaceutical products under this HS code.
Morocco
1. Drug Regulatory Authority: Ministry of Health, Directorate of Medicines and Pharmacy.
2. Import Registration Process for Imatinib: Importers must obtain a marketing authorization by submitting an application that includes product specifications, clinical data, and manufacturing details.
3. Estimated Timeline for Registration: The registration process can take between 12 to 24 months, depending on the complexity of the application and any additional information requested.
4. Import Tariff/Duty for HS 30049049: Morocco imposes a customs duty of 2.5% on pharmaceutical products under this HS code.
Demand Drivers & Market Opportunity
TransData Nexus Imatinib buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Imatinib across various countries is primarily driven by the prevalence of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST), conditions for which Imatinib is a first-line treatment. According to the World Health Organization (WHO), CML accounts for approximately 15% of all leukemia cases worldwide, indicating a significant patient population requiring Imatinib therapy.
Government healthcare programs and the expansion of universal health coverage have further bolstered demand. Many countries have included Imatinib in their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which recommends Imatinib for the treatment of CML and GIST. This inclusion facilitates procurement through government tenders and international organizations like UNICEF and the Global Fund, ensuring broader access to the medication. The presence of 456 buyers across 119 countries, as per TransData Nexus data, underscores the global reach and critical need for Imatinib in managing these life-threatening conditions.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 456 global importers of Imatinib identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 1,726 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 119 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,726 Verified Shipments
456 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists